New RA drug enters first human tests
Symptom relief
Recruiting now
This early-stage study tests a new drug called KT501 in 24 adults with moderate to severe rheumatoid arthritis (RA). The main goal is to check safety and how the body processes the drug after a single injection. Participants must have had RA for at least 6 months and not responde…
Phase: PHASE1 • Sponsor: Kali Therapeutics, Inc. • Aim: Symptom relief
Last updated May 19, 2026 12:00 UTC